2.3.1.B41	down	decline of SIRT6 expression when bladder cancer progresses from stage T2 to stage T4	729849	
2.3.1.B41	down	enzyme expression is significantly reduced in human ovarian cancer tissues compared to the normal tissues	738169	
2.3.1.B41	down	H2O2 treatment significantly reduces Sirt6 protein. Stress-induced downregulation of Sirt6 is likely involved in the pathogenesis of diabetic retinopathy	729362	
2.3.1.B41	down	high-glucose causes Sirt6 and p-AMPK downregulation in podocytes. High-glucose conditions decrease Sirt6 expression levels significantly	756973	
2.3.1.B41	down	high-glucose conditions decrease Sirt6 expression levels significantly	-, 756973	
2.3.1.B41	down	in cortical and hippocampal neurons SIRT6 is downregulated during maturation in vitro, reaching the lowest expression at 11 days in vitro	730473	
2.3.1.B41	down	in Hep-G2 cells, doxorubicin treatment results in significant increases in SIRT1 and SIRT4 mRNA expression and downregulation of SIRT6 mRNA level by 36 h	757883	
2.3.1.B41	down	minute cholesterol crystals significantly suppress SIRT6 expression in endothelial cells	756672	
2.3.1.B41	down	several factors regulate the expression of the SIRT6 gene. PARP1 may inhibit the expression of SIRT6, and the presence of PJ-34, a PARP1 inhibitor, results in enhanced mRNA level of nuclear SIRT6. A role for the transcription factor E2F1 as an enhancer of glycolysis and inhibitor of the expression of SIRT6. E2F1 directly binds the SIRT6 promoter and suppresses SIRT6 promoter activity under both normoxic and hypoxic culture conditions. In embryos and neural stem cells, SIRT6 expression becomes suppressed by maternal diabetes in vivo or high glucose in vitro through oxidative stress	757931	
2.3.1.B41	down	several factors regulate the expression of the SIRT6 gene. PARP1 may inhibit the expression of SIRT6, and the presence of PJ-34, a PARP1 inhibitor, results in enhanced mRNA level of nuclear SIRT6. A role for the transcription factor E2F1 as an enhancer of glycolysis and inhibitor of the expression of SIRT6. E2F1 directly binds the SIRT6 promoter and suppresses SIRT6 promoter activity under both normoxic and hypoxic culture conditions. In neural stem cells, SIRT6 expression becomes suppressed by maternal diabetes in vivo or high glucose in vitro through oxidative stress	757931	
2.3.1.B41	down	SIRT6 is down-regulated in human glioma tissues	729145	
2.3.1.B41	up	during mitosis, the Sirt6 expression level is increased	730527	
2.3.1.B41	up	enzyme expression in HCC cells is upregulated by transforming growth factor-beta1, H2O2, and HOCl	737977	
2.3.1.B41	up	inhibition of SIRT5 significantly promotes SIRT6 expression	755904	
2.3.1.B41	up	several factors regulate the expression of the SIRT6 gene. Notably, in a tumor-suppressing pathway, c-FOS binds to an AP-1 binding site (TAAGTCA) at the SIRT6 promoter, activating SIRT6 gene expression. In addition to the positive regulators of SIRT6, various chromatin factors negatively control the gene expression of SIRT6. presence of PJ-34, a PARP1 inhibitor, results in enhanced mRNA level of nuclear SIRT6	757931	
2.3.1.B41	up	SIRT6 expression is upregulated under pathologic conditions in angiotensin II-stimulated cardiac fibroblasts and in myocardium of rat subjected to abdominal aortic constriction surgery	739733	
2.3.1.B41	up	SIRT6 is upregulated in squamous cell carcinoma	729520